Genetic determinants of lipid aberrations in patents with essential hypertension

Authors

  • V. V. Buriak Zaporizhzhia State Medical University, Ukraine,
  • V. A. Vizir Zaporizhzhia State Medical University, Ukraine,
  • O. V. Demidenko Zaporizhzhia State Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2310-1210.2020.2.200564

Keywords:

apolipoprotein E, genetic polymorphism, essential hypertension, dyslipidemia

Abstract

 

Aim. To reveal the relationship between apolipoprotein E gene polymorphism and lipid spectrum modification in patients with essential hypertension.

Materials and methods. The lipid spectrum components and apolipoprotein E gene polymorphism were analyzed in 310 patients with essential hypertension.

Results. The mean plasma levels of total cholesterol, high and low density lipoproteins, triglycerides and the atherogenic index were 5.18 ± 0.08 mmol/l, 1.32 ± 0.03 mmol/l, 3.06 ± 0.07 mmol/l, 1.74 ± 0.05 mmol/l and 3.21 ± 0.08, respectively. In patients with essential hypertension, the genetic polymorphism of apolipoprotein E was characterized by the alleles E2 (13.26 %), E3 (93.87 %) and E4 (30.65 %) presence. Based on single nucleotide polymorphism identification, there were defined the following genotypes: E2/E2 (0.65 %), E2/E3 (10.97 %), E2/E4 (1.61 %), E3/E3 (57.74 %), E3/E4 (25.16 %) and E4/E4 (3.87 %). Individuals with E2/E4 genotype had higher levels of total cholesterol (+17.56 %, P < 0.05) and low density lipoproteins (+25.7 %, P < 0.01), and atherogenic index was increased (+38.18 %, P < 0.05) in E4/E4 carriers in comparison with E2/E3. Hypertonic E4/E4 carriers were found to have elevated plasma triglycerides (+20.23 %, P < 0.05) in comparison with E3/E3, as well as increased triglycerides (+25.3 %, p < 0.05) and very low density lipoproteins (+25.33 %, P < 0.05) in comparison with E3/E4 carriers. E3/E3 and E3/E4 carriers demonstrated decrease in total cholesterol (-12.9 %, P < 0.05) and (-11.04 %, P < 0.05), respectively, as well as low density lipoproteins (-15.69 %, P < 0.001) and (-11.48 %, P < 0.05), respectively, as compared to E2/E4. The plasma content of high density lipoproteins was not dependent on ApoE genotype.

Conclusions. In patients with essential hypertension, the most common allele is E3 (93.87 %) and the E3/E3 genotype (57.74 %), while the E3/E4 genotype is 25.16 %. Presence of the E2/E4 genotype is significantly associated with the elevated total cholesterol and low density lipoproteins plasma levels, whereas the E4/E4 genotype is accompanied by the increased triglycerides, low density lipoproteins levels and atherogenic index.

 

References

World Health Organization. (‎2018, June 1)‎. Noncommunicable diseases. https://www.who.int/ru/news-room/fact-sheets/detail/noncommunicable-diseases.

Mendis, S., Puska, P., & Norrving, B. (Eds.). (2011). Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization. https://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/.

Townsend, N., Wilson, L., Bhatnagar, P., Wickramasinghe, K., Rayner, M., & Nichols, M. (2016). Cardiovascular disease in Europe: epidemiological update 2016. European Heart Journal, 37(42), 3232-3245. https://doi.org/10.1093/eurheartj/ehw334

Forouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., Cohen, A. J., Dandona, L., Estep, K., Ferrari, A. J., Frostad, J. J., Fullman, N., Gething, P. W., Godwin, W. W., Griswold, M., … Murray, C. J. L. (2016). Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet, 388(10053), 1659-1724. https://doi.org/10.1016/s0140-6736(16)31679-8

World Health Organization. (‎2014)‎. Global status report on noncommunicable diseases 2014. World Health Organization. https://apps.who.int/iris/handle/10665/148114

Zhou, B., Bentham, J., Di Cesare, M., Bixby, H., Danaei, G., Cowan, M. J., Paciorek, C. J., Singh, G., Hajifathalian, K., Bennett, J. E., Taddei, C., Bilano, V., Carrillo-Larco, R. M., Djalalinia, S., Khatibzadeh, S., Lugero, C., Peykari, N., Zhang, W. Z., Lu, Y., … Zuñiga Cisneros, J. (2017). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19•1 million participants. The Lancet, 389(10064), 37-55. https://doi.org/10.1016/s0140-6736(16)31919-5

Suchard, M. A., Schuemie, M. J., Krumholz, H. M., You, S. C., Chen, R., Pratt, N., Reich, C. G., Duke, J., Madigan, D., Hripcsak, G., & Ryan, P. B. (2019). Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. The Lancet, 394(10211), 1816-1826. https://doi.org/10.1016/s0140-6736(19)32317-7

Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., Kahan, T., Mahfoud, F., Redon, J., Ruilope, L., Zanchetti, A., Kerins, M., Kjeldsen, S. E., Kreutz, R., Laurent, S., … Brady, A. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 39(33), 3021-3104. https://doi.org/10.1093/eurheartj/ehy339

McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., & Ford, I. (2014). Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. European Heart Journal, 35(5), 290-298. https://doi.org/10.1093/eurheartj/eht232

Mistry, H., Morris, S., Dyer, M., Kotseva, K., Wood, D., & Buxton, M. (2012). Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach. British Medical Journal Open, 2(5), Article e001029. https://doi.org/10.1136/bmjopen-2012-001029

Pereira, M., Azevedo, A., Lunet, N., Carreira, H., O’Flaherty, M., Capewell, S., & Bennett, K. (2013). Explaining the Decline in Coronary Heart Disease Mortality in Portugal Between 1995 and 2008. Circulation: Cardiovascular Quality and Outcomes, 6(6), 634-642. https://doi.org/10.1161/circoutcomes.113.000264

Banegas, J. R., Lopez-Garcia, E., Dallongeville, J., Guallar, E., Halcox, J. P., Borghi, C., Masso-Gonzalez, E. L., Jimenez, F. J., Perk, J., Steg, P. G., De Backer, G., & Rodriguez-Artalejo, F. (2011). Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. European Heart Journal, 32(17), 2143-2152. https://doi.org/10.1093/eurheartj/ehr080

De Smedt, D., Kotseva, K., De Bacquer, D., Wood, D., De Backer, G., Dallongeville, J., Seppo, L., Pająk, A., Reiner, Ž., Vanuzzo, D., Georgiev, B., Gotcheva, N., & Annemans, L. (2012). Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project. European Heart Journal, 33(22), 2865-2872. https://doi.org/10.1093/eurheartj/ehs210

World Health Organization. (‎2018)‎. Noncommunicable diseases country profiles 2018. World Health Organization. https://apps.who.int/iris/handle/10665/274512

Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., Graham, I., Hall, M. S., Hobbs, F. D. R., Løchen, M.-L., Löllgen, H., Marques-Vidal, P., Perk, J., Prescott, E., Redon, J., … ESC Scientific Document Group. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal, 37(29), 2315-2381. https://doi.org/10.1093/eurheartj/ehw106

Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., Reiner, Ž., Riccardi, G., Taskinen, M.-R., Tokgozoglu, L., Verschuren, W. M. M., Vlachopoulos, C., Wood, D. A., & Zamorano, J. L. (2016). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 37(39), 2999-3058. https://doi.org/10.1093/eurheartj/ehw272

Futema, M., Shah, S., Cooper, J. A., Li, K., Whittall, R. A., Sharifi, M., Goldberg, O., Drogari, E., Mollaki, V., Wiegman, A., Defesche, J., D’Agostino, M. N., D’Angelo, A., Rubba, P., Fortunato, G., Waluś-Miarka, M., Hegele, R. A., Aderayo Bamimore, M., Durst, R., … Humphries, S. E. (2015). Refinement of Variant Selection for the LDL Cholesterol Genetic Risk Score in the Diagnosis of the Polygenic Form of Clinical Familial Hypercholesterolemia and Replication in Samples from 6 Countries. Clinical Chemistry, 61(1), 231-238. https://doi.org/10.1373/clinchem.2014.231365

Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., Hovingh, G. K., Humphries, S. E., Kovanen, P. T., Masana, L., Pajukanta, P., Parhofer, K. G., Raal, F. J., Ray, K. K., Santos, R. D., … Wiklund, O. (2014). The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. The Lancet Diabetes & Endocrinology, 2(8), 655-666. https://doi.org/10.1016/s2213-8587(13)70191-8

Buriak, V. V., & Vizir, V. A. (2016). Geneticheskii polimorfizm apolipoproteinov: prognosticheskoe znachenie detektsii i perspektivy klinicheskoi applikatsii [Apolipoprotein genetic polymorphism: detection prognostic value and clinical application perspectives]. Molodyi vchenyi, (10), 49-53. http://molodyvcheny.in.ua/files/journal/2016/10/12.pdf. [in Russian].

Kutko, I. I., & Matiushenko, I. Yu. (2016). Perspektyvy rozvytku biomedytsyny na osnovi NBIC-tekhnolohii v krainakh svitu i Ukraini [Prospects for the development of biomedicine based on NBIC technologies in countries around the world and in Ukraine]. Novyny medytsyny ta farmatsii, (3), 16-19. http://www.mif-ua.com/archive/article/42492. [in Ukrainian].

Kovaleva, O. N., Belovol, A. N., & Vinogradova, S. V. (2008). Rol' ɛ2/ɛ3/ɛ4-polimorfizma gena apolipoproteina E v razvitii dislipoproteinemii i ateroskleroza (obzor literatury) [Role оf ɛ2/ɛ3/ɛ4-polymorphism оf apolipoprotein gеinе in тhе development оf dyslipoproteinemia and atherosclerosis (review of literature)]. Zhurnal AMN Ukrainy, 14(2), 218-234 [in Russian].

Porta, M. S. (Ed.). (2014). A Dictionary of Epidemiology (6th ed.). Oxford University Press.

Derzhavnyi ekspertnyi tsentr MOZ Ukrainy, & Asotsiatsiia kardiolohiv Ukrainy. (2017). Arterialna hipertenziia: klinichna nastanova: zatv. nakazom MOZ Ukrainy vid 24.05.2012 roku № 384. [Arterial hypertension: clinical guideline. Approved by Order of the Ministry of Health of Ukraine from May 24, 2012 № 384]. https://dec.gov.ua/wp-content/uploads/2019/11/kn_artergipert.pdf. [in Ukrainian].

Hickman, P. E. (2007). Recommendations for lipid testing and reporting by Australian pathology laboratories. Pathology, 39(3), 297-298. https://doi.org/10.1080/00313020701358129

(2019, November 5). APOE. SNPedia. https://www.snpedia.com/index.php/APOE.

Rumyantsev, P. O., Saenko, V. A., & Rumyantseva, U. V. (2009). Statisticheskie metody analiza v klinicheskoi praktike. Chast' І. Odnomernyi statisticheskii analiz [Statistical methods for the analyses in clinical practice. Part 1. Univariate statistical analysis]. Problemy endokrinologii, 55(5), 48-55. https://doi.org/10.14341/probl200955548-55 [in Russian].

Buriak, V. V. (2011). Lipidnyi spektr ta vmist homotsysteinu u khvorykh z arterialnoiu hipertenziieiu, asotsiiovanoiu z patolohiieiu ekstrakranialnykh arterii. (Avtoref. dis. … kand. med. nauk). [Lipid spectre and homocysteine content in patients with arterial hypertension, associated with extracranial arteries pathology]. (Extended abstract of candidate’s thesis). Zaporizhzhia. [in Ukrainian].

Voevoda, M. I., Schakhtschneider, E. V., Maximov, V. N., Kulikov, I. V., & Romashchenko, A. G. (2008). Polimorfizm gena apolipoproteina E i ateroskleroz [Polymorphism of apolipoprotein E gene and atherosclerosis]. Ateroskleroz, 4(1), 11-26. [in Russian].

Malashenkova, I. K., Krynskiy, S. A., Mamoshina, M. V., & Didkovskiy, N. A. (2018). Polimorfizm gena AROE: vliyanie allelya AROE4 na sistemnoe vospalenie i ego rol' v patogeneze bolezni Al'tsgeimera [ApoE gene polymorphism: the impact of ApoE4 allele on systemic inflammation and its role in the pathogenesis of Alzheimer’s disease. Medical Immunology]. Meditsinskaya immunologiya, 20(3), 303-312. https://doi.org/10.15789/1563-0625-2018-3-303-312 [in Russian].

Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G., & Frikke-Schmidt, R. (2019). Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort. European Heart Journal, 40(33), 2813-2824. https://doi.org/10.1093/eurheartj/ehz402

How to Cite

1.
Buriak VV, Vizir VA, Demidenko OV. Genetic determinants of lipid aberrations in patents with essential hypertension. Zaporozhye Medical Journal [Internet]. 2020Apr.13 [cited 2024Jul.17];22(2). Available from: http://zmj.zsmu.edu.ua/article/view/200564

Issue

Section

Original research